CoChat

Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial

Open access
van den Elsen, Geke A.H., Ahmed, Amir I.A., Verkes, Robbert-Jan, Kramers, Cees, Feuth, Ton, Rosenberg, Paul B., van der Marck, Marjolein A., Olde Rikkert, Marcel G.M. · 2015 · Neurology
Cited by 164

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Objective: To study the efficacy and safety of low-dose oral tetrahydrocannabinol (THC) in the treatment of dementia-related neuropsychiatric symptoms (NPS). Methods: This is a randomized, double-blind, placebo-controlled study. Patients with dementia and clinically relevant NPS were randomly assigned to receive THC 1.5 mg or matched placebo (1:1) 3 times daily for 3 weeks. Primary outcome was change in Neuropsychiatric Inventory (NPI), assessed at baseline and after 14 and 21 days. Analyses were based on intention-to-treat. Results: Twenty-four patients received THC and 26 received placebo. NPS were reduced during both treatment conditions. The difference in reduction from baseline between THC and placebo was not significant (mean difference NPItotal: 3.2, 95% confidence interval [CI] −3.6 to 10.0), nor were changes in scores for agitation (Cohen-Mansfield Agitation Inventory 4.6, 95% CI −3.0 to 12.2), quality of life (Quality of Life–Alzheimer's Disease −0.5, 95% CI −2.6 to 1.6), or activities of daily living (Barthel Index 0.6, 95% CI −0.8 to 1.9). The number of patients experiencing mild or moderate adverse events was similar (THC, n = 16; placebo, n = 14, p = 0.36). No effects on vital signs, weight, or episodic memory were observed. Conclusions: Oral THC of 4.5 mg daily showed no benefit in NPS, but was well-tolerated, which adds valuable knowledge to the scarce evidence on THC in dementia. The benign adverse event profile of this dosage allows study of whether higher doses are efficacious and equally well-tolerated. Classification of evidence: This study provides Class I evidence that for patients with dementia-related NPS, low-dose THC does not significantly reduce NPS at 21 days, though it is well-tolerated. AD= : Alzheimer disease; AE= : adverse event; CCGIC= : Caregiver Clinical Global Impression of Change; CI= : confidence interval; CMAI= : Cohen-Mansfield Agitation Inventory; NPI= : Neuropsychiatric Inventory; NPS= : neuropsychiatric symptoms; PAL WMS-R= : Paired Associate Learning Wechsler Memory Scale–Revised; QoL-AD= : Quality of Life–Alzheimer's Disease Scale; RCT= : randomized controlled trial; THC= : Δ-9-tetrahydrocannabinol

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000001675

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 164

Metadata

Authors
van den Elsen, G. A. H., Ahmed, A. I. A., Verkes, R.-J., Kramers, C., Feuth, T., Rosenberg, P. B., van der Marck, M. A., & Olde Rikkert, M. G. M.
Venue
Neurology
Published
2015-06-09
Volume
84
Issue
23
Pages
2338-2346
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2099611723
Cited by
164
References
16
FWCI
6.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. https://app.cochat.ai/papers/10.1212/wnl.0000000000001675
The paper
van den Elsen, G. A. H., Ahmed, A. I. A., Verkes, R.-J., Kramers, C., Feuth, T., Rosenberg, P. B., van der Marck, M. A., & Olde Rikkert, M. G. M. (2015). Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology. https://doi.org/10.1212/wnl.0000000000001675

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.